Literature DB >> 20503481

Circulating obestatin levels in normal and Type 2 diabetic subjects.

D H St-Pierre1, F Settanni, I Olivetti, E Gramaglia, M Tomelini, R Granata, F Prodam, A Benso, E Ghigo, F Broglio.   

Abstract

BACKGROUND: Obestatin has been discovered as a new product of the ghrelin gene. Its physiological actions are still a matter of debate, but it seems that this peptide is likely to be involved in the control of insulin secretion and action as well as of adipocyte function. It has been already shown that obestatin secretion in humans is negatively modulated by food intake. AIM: To clarify obestatin secretion in normal subjects and in patients with Type 2 diabetes (T2D) in basal conditions and after a standardized meal. SUBJECTS/
METHODS: Five normal subjects and 5 T2D patients were studied during infusion of saline (iv for over 5 h from -120 to +180 min). A standardized lunch was served at 0 min. Obestatin, glucose, and insulin levels were assayed at -120, -90, -60, -45, -30, -15, 0, 15, 30, 45, 60, 90, 120, 150, and 180 min.
RESULTS: From -120 to 0 min, obestatin levels in normal and T2D subjects were similar (area under the curve: 32.3+/-5.6 pg/ml/min vs 31.1+/-1.0 pg/ml/min). After the meal, circulating obestatin levels underwent a clear decrease in normal subjects (0 min: 300.6+/-34.7 pg/ml vs nadir at 60 min: 161.8+/-29.4 pg/ml; p=0.002) but not in diabetic patients (0 min: 267.2+/-16.5 pg/ml vs nadir at 180 min: 226.0+/-10.5 pg/ml).
CONCLUSION: This study shows that normal and diabetic subjects display similar levels of circulating obestatin in fasting condition. However patients with T2D look refractory to the inhibitory effect of meal on obestatin secretion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503481     DOI: 10.1007/BF03345780

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  28 in total

1.  Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus.

Authors:  Xiaoya Qi; Ling Li; Gangyi Yang; Jianlei Liu; Ke Li; Yi Tang; Hua Liou; Guenther Boden
Journal:  Clin Endocrinol (Oxf)       Date:  2007-04       Impact factor: 3.478

2.  Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake.

Authors:  Jian V Zhang; Pei-Gen Ren; Orna Avsian-Kretchmer; Ching-Wei Luo; Rami Rauch; Cynthia Klein; Aaron J W Hsueh
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

3.  GPR39 signaling is stimulated by zinc ions but not by obestatin.

Authors:  Birgitte Holst; Kristoffer L Egerod; Enrico Schild; Steve P Vickers; Sharon Cheetham; Lars-Ole Gerlach; Laura Storjohann; Carsten E Stidsen; Rob Jones; Annette G Beck-Sickinger; Thue W Schwartz
Journal:  Endocrinology       Date:  2006-09-07       Impact factor: 4.736

4.  Effect of peripheral obestatin on gastric emptying and intestinal contractility in rodents.

Authors:  B De Smet; T Thijs; T L Peeters; I Depoortere
Journal:  Neurogastroenterol Motil       Date:  2007-03       Impact factor: 3.598

5.  Circulating preprandial ghrelin to obestatin ratio is increased in human obesity.

Authors:  Zhi-Fu Guo; Xing Zheng; Yong-Wen Qin; Jian-Qiang Hu; Shao-Ping Chen; Zheng Zhang
Journal:  J Clin Endocrinol Metab       Date:  2007-02-13       Impact factor: 5.958

6.  Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects.

Authors:  Dominik G Haider; Karin Schindler; Gerhard Prager; Arthur Bohdjalian; Anton Luger; Michael Wolzt; Bernhard Ludvik
Journal:  J Clin Endocrinol Metab       Date:  2006-12-12       Impact factor: 5.958

7.  Characteristics associated with fasting appetite hormones (obestatin, ghrelin, and leptin).

Authors:  Jeannette M Beasley; Brett A Ange; Cheryl A M Anderson; Edgar R Miller Iii; Janet T Holbrook; Lawrence J Appel
Journal:  Obesity (Silver Spring)       Date:  2008-12-04       Impact factor: 5.002

Review 8.  Central and peripheral roles of ghrelin on glucose homeostasis.

Authors:  Yuxiang Sun; Mark Asnicar; Roy G Smith
Journal:  Neuroendocrinology       Date:  2007-09-26       Impact factor: 4.914

9.  Obestatin reduces food intake and suppresses body weight gain in rodents.

Authors:  Guy J Lagaud; Andy Young; Auzon Acena; Magda F Morton; Terrance D Barrett; Nigel P Shankley
Journal:  Biochem Biophys Res Commun       Date:  2007-03-30       Impact factor: 3.575

10.  Inhibitory effect of obestatin on glucose-induced insulin secretion in rats.

Authors:  An-Jing Ren; Zhi-Fu Guo; Yang-Kai Wang; Li-Gang Wang; Wei-Zhong Wang; Li Lin; Xing Zheng; Wen-Jun Yuan
Journal:  Biochem Biophys Res Commun       Date:  2008-03-07       Impact factor: 3.575

View more
  4 in total

1.  The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling.

Authors:  Andrew J Agnew; Emma Robinson; Carmel M McVicar; Adam P Harvey; Imran H A Ali; Jennifer E Lindsay; Denise M McDonald; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease.

Authors:  Michael Estep; Massih Abawi; Mohammed Jarrar; Lei Wang; Maria Stepanova; Hazem Elariny; Amir Moazez; Zachary Goodman; Vikas Chandhoke; Ancha Baranova; Zobair M Younossi
Journal:  Obes Surg       Date:  2011-11       Impact factor: 4.129

3.  Relevance of plasma obestatin and early arteriosclerosis in patients with type 2 diabetes mellitus.

Authors:  Peng-Ying Gu; Dong-Mei Kang; Wei-Dong Wang; Yan Chen; Zhi-Hong Zhao; Hui Zheng; Shan-Dong Ye
Journal:  J Diabetes Res       Date:  2013-11-17       Impact factor: 4.011

Review 4.  Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Authors:  Elaine Cowan; Kerry J Burch; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2016-05-27       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.